Here is an analysis at the scorecard of Cellular Biomedicine Group Inc. (NASDAQ:CBMG) for the recent quarter and analyst projections for the coming periods.
The firm generated sales of 98,425%, implying a jump of -3.98% compared to a analogous quarter a year ago.
To achieve the recorded sales of 98,425% for the quarter, the firm incurred $707,141 in cost of goods. Hence, after considering the cost of sales, Cellular Biomedicine Group Inc. came with a gross income of $(608,716).
Let’s look into the technical of the stock
The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction. Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.
Cellular Biomedicine Group Inc. incurred other expenses in the completion of operation. Taking those into account, it closed the quarter with EPS of $(0.43). The firm had 14.28M diluted outstanding shares at the close of the quarter.
For the next quarter, analysts on the average are projecting EPS of $-0.47.
Cellular Biomedicine Group Inc.’s cash balance at the close of the recent quarter was 33.36M%. The firm generated free cash flow of $(5.89M) during the quarter, while net operating cash flow was $(4.86M). Net change in cash was $(5.89M).
What is market thinking about Cellular Biomedicine Group Inc.? So far 1 analysts have assessed the stock, and they have average recommendation of Buy and average price target of $18.00. To put the recommendation into perspective, call in the range of 1.00 – 1.24 indicates a BUY recommendation, whereas 1.25 – 1.74 refers to OVERWEIGHT. HOLD recommendation is shown by 1.75 ? 2.24, UNDERWEIGHT is signified by 2.25 – 2.74 while SELL is signified by 2.75 – 3.00.
Does Cellular Biomedicine Group Inc. have a strong balance sheet? A look at the firm’s balance sheet at the close of the most recent quarter displays that it has total assets of $63.59M, offset by total liabilities of $2.37M.
Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the Company’s Board of Directors (the “Board”) has approved a new stock repurchase program granting the company authority to repurchase up to $10 million in common shares (the “2017 Stock Repurchase Program”) through open market purchases pursuant to a plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and in accordance with Rule 10b-18 of the Exchange Act.